CGEN
Companies
NASDAQ
Compugen Ltd.
Health Care
$1.70
+$0.17 (+11.11%)
Price Chart
Overview
About CGEN
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
Market Cap
$188.9M
Volume
384.0K
Avg. Volume
521.1K
P/E Ratio
-11.727272
Dividend Yield
0.00%
Employees
43.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.56
High Correlation
Volatility
High (0.83)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Low Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, CGEN shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$188.9M
Volume384.0K
P/E Ratio-11.73
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 4, 2025Related Securities
Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025